Improving treatment of solid cancers by nanoconjugate-mediated immune conversion of tumour cells
Nat Nanotechnol
.
2022 Dec;17(12):1243-1244.
doi: 10.1038/s41565-022-01244-8.
Authors
Zhenghai Tang
1
,
André Veillette
2
3
4
Affiliations
1
Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec, Canada.
2
Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec, Canada. andre.veillette@ircm.qc.ca.
3
Department of Medicine, University of Montréal, Montréal, Québec, Canada. andre.veillette@ircm.qc.ca.
4
Department of Medicine, McGill University, Montréal, Québec, Canada. andre.veillette@ircm.qc.ca.
PMID:
36357791
DOI:
10.1038/s41565-022-01244-8
No abstract available
Publication types
Comment
MeSH terms
Drug Delivery Systems
Humans
Nanoconjugates*
Neoplasms* / therapy
Substances
Nanoconjugates